[Noáin, Spain, October 26, 2020]3P Biopharmaceuticals,
a leading Contract Development and Manufacturing Organization (CDMO)
specialized in process development and cGMP manufacturing of biologics,
has signed a manufacturing agreement withSpyBiotech, a company with a
novel vaccine platform to target infectious diseases, cancer and chronic diseases.
Oxford, UK-based SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021.This carrier will be used to display antigens from different pathogens.
SpyBiotech’s proprietary SpyCatcher/SpyTag is a platform technology which allows antigens to be displayed onto virus-like particles (VLPs) with a covalent, irreversible bond in a highly stable and effective way with specific orientation/epitope presentation and high density. The technology can be used for an exceptionally broad range of applications in vaccine development and has established proof of concept data in viral, bacterial, parasitic diseases as well as chronic diseases and cancer.
As 3P Biopharmaceuticals CEO Dámaso Molero explains: "It is amazing being part of a project which presents an opportunity to develop treatments for a broad range of diseases. We are helping to support manufacturing which we believe will open the door for pioneering vaccines which could offer a hope for improving the lives of many people. That is extremely exciting.”
Genevieve Labbe, Senior Scientist and GMP Project Manager for SpyBiotech commented: “It’s critical to have a trusted partner in place for cell line and cGMP production. SpyBiotech is looking forward to advancing this product and we are delighted to be working with 3P Biopharmaceuticals, a leading CDMO.”
Through this partnership, 3P Biopharmaceuticals will once again demonstrate its capacity to carry out processes and manufacturing of molecules developed for diverse therapeutic applications, helping to consolidate its competitive position as one of the most trusted CDMOs in Europe.
About 3P Biopharmaceuticals
3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market. For further information: http://www.3pbio.com/
About SpyBiotech
SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimises delivery risk and enhances immunogenicity and efficacy. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialise and sub-license the SpyTag/SpyCatcher technology in vaccine development. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for 2021. SpyBiotech is supported by high quality investors including Oxford Sciences Innovation (OSI), the capital investor for the University of Oxford, and GV (formally Google Ventures). The company has raised Ł15 million of funding to date. For further information: https://www.spybiotech.com/
3P Biopharmaceuticals contact:
Isabel García, Communications & Marketing at 3P Biopharmaceuticals
Phone: + 34 948 346 480 / email: igarcia@3pbio.com
|
.jpg)
